thanks all for your replies ... but apart from the predictable name calling, not one reasoned answer to my rather straight forward question. Is it correct that the company was focused on selling stock to the public in the $1.40-$2.00 range just months ago, in the hype period leading up to the Gen 1 review in May? Now, at the historic low price of .38 cents a share, no insider has stepped up to snap up shares. In my opinion that's curious, as I thought they would have by now based on their long-term conviction. I see the last insider purchases over a year ago.
I wouldn't. I mean, why would you waste your time with such a post? I'm sure you're probably a paid basher, but as an actual retail investor holding worthless shares of this company, I actually agree with you.
The company is not in a very strong position right now. Hard to say if they'll ever recover from this landslide. Definitely not getting the go ahead in September, and Gen 2 Trials will be a must if they ever expect to see approval in the US.